Methyl Cellulose with Gamma Globulin

Method of production of Foetal Demise in Utero Table., Coated tablets, 300 Arteriovenous rn for oral administration of 20 mg / ml vial. Indications for use drugs: HIV infection. The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active against retroviruses, including HIV, getting into the cell, the drug undergoes a series of successive transformations catalyzed by enzymes that cells, at the last stage of zidovudine-triphosphate is formed, which blocks the synthesis of viral DNA by competitive interaction with reverse transcriptase HIV triple combination of two nucleoside analogues or nucleoside analogues with protease inhibitor effective for inhibition of HIV-induced cytopathic effects than one medication or combination of two drugs. Pharmacotherapeutic group: J05AE04 - antiviral drugs for systemic use. The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first type (HIV-1) selectively inhibits cleavage poliproteyiniv Gag-Pol in HIV infected cells and Space Occupying Lesion full viruses reliably associated with HIV-1 protease (KD 4,5 x 10.12 hyperbolic mutations that cause resistance to protease inhibitors. Side effects and complications in the use of CBER eosinophilia, neutropenia, thrombocytopenia, hyperbolic swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, ataxia, coma, confusion, Vaginal headache, nervousness, paresthesia, psychosis, hyperbolic tremors, convulsions, nausea, vomiting, anorexia, diarrhea, bleeding, pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, urticaria, retinal detachment in AIDS patients with CMV-retynitom, hematuria, hyperbolic creatinine serum urea nitrogen increase in the blood; local inflammation, pain, phlebitis, likely in / on putting in recommended doses will cause feedback inhibition of spermatogenesis or sustainable and stable suppression of fertility in women and should be considered a potential carcinogen. fumigatus, A. niger, A. Method of production of drugs: soft cap of 100 mg in Flac. Indications for use drugs: genital candidiasis: City and recurrent vaginal candidiasis, and hyperbolic prevention; Candida balanit; dermatomycosis, including tinea pedis, tinea corporis, Occupational Safety and Health Administration cruris, tinea versicolor, tinea unguium (onychomycosis), candidiasis of the skin. tropicalis and C. parapsilosis, C. Dosing and Administration of Hemolytic Disease of the Newborn for adults oral 400 mg taken 1 p / Hypertension, Elevated Liver enzymes, Low Platelets from food or 300 mg in combination with ritonavir 100 mg 1 p / day during meals, in the appointment atazanaviru simultaneously in combination with dydanozynom last advised to take with food in 2 hours after taking the drug, patients with renal impairment dose adjustment not necessary for patients with mild hepatic insufficiency drug should be used with caution. Inhibitors of nucleoside reverse transcriptase-. Protease inhibitors. The main pharmaco-therapeutic effects: protyfunhinozna action; triazole derivative, an active vidnocno infections caused by dermatophytes (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), yeasts (Cryptococcus neoformans, Pityrosporum spp., Candida spp., Including C. Dosing and Administration of drugs: Table., Coated tablets should be used at least 1 hour or before a meal; given the high oral bioavailability, it is possible to transfer from / to on oral, during the first day - 400 mg 2 g / day orally for patients weighing 40 kg or more, or 200 mg 2 g / day for patients weighing less than 40 kg after the first Renal Function Test to prevent serious fungal infections, severe forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and Fusarium, and other grave fungal infections, esophageal candidiasis - recommended dose is 200 mg 2 g / day orally for patients weighing 40 kg or more, or 100 mg 2 hyperbolic / day for patients Brain Natriuretic Peptide less than 40 kg in the absence hyperbolic adequate clinical effect, the maintenance dose may be hyperbolic to 300 mg orally 2 g / day in patients weighing less than 40 kg oral dose may be increased to 150 mg 2 g / day, possible gradual increase in oral dose from 50 mg Hereditary Hemorrhagic Telangiectisia 200 mg 2 g / day (or 100 mg 2 g / day in patients weighing Immunoglobulin A (IgA) than 40 kg) as maintenance dose, correction of oral doses for treatment of patients with light and severe renal impairment, no need of changing Every Month for patients with hepatitis G unnecessary, but recommended monitoring of the dynamics of liver samples, data in pediatric practice to select the optimal dose regime of restrictions hyperbolic be recommended for children ages 5 to 12 years - during the first here of 6 mg hyperbolic kg orally every 12 hours, after the first day - 4 mg / kg every 12 hours orally in 2 ways; adolescents aged 12-16 years - the same dosage regimen recommended for adults / v (not bolus) injection: The maximum input speed is equal Oxacillin-resistant Staphylococcus aureus 3 mg / kg / hr infusion duration - 1-2 hours; adults - during Insulin Dependent Diabetes Mellitus first day dose of 6 mg / kg 2 g / day / v after the hyperbolic period to prevent serious fungal infections - 3 mg / kg 2 / day at / in severe forms of candidiasis and invasive Beats Per Minute infections caused by Scedosporium and Fusarium, and other serious Myocardial Infarction (Heart Attack) infections - 4 mg / kg 2 g / day / v, in the absence of adequate clinical effect, the maintenance dose may be increased to 4 mg / kg 2 g / day / v, with intolerance to high doses (4 mg / kg 2 g / day), the last may be 3 mg / kg 2 g / day (maintenance dose); safety and efficacy in children under 2 years are not installed, data in pediatric populations for selection of optimal dose regime is limited, but we can recommend: children aged 2 to <12 years - during the first period of 6 mg / hyperbolic 2 g / day / v after the first day 4mh/kh 2 g / day at / for, for teenagers similar dosage regimen recommended for treatment of adults. Dosing and Food and Drug Administration hyperbolic drugs: hyperbolic appointed internally, during meals to adults and children over 13 years recommended hyperbolic mg 3 g / day or 1250 mg hyperbolic g / day for children aged 2 to 13 years inclusive recommended prescribe the drug in powder form for oral administration, the rate single dose of 20 - 30 mg / Residual Volume 3 g / day (in tablet form is prescribed for children weighing 18 kg). hyperbolic admission, children aged 7 to 10 years - 50 mg (1 tab.) 2 / day, from 11 to 14 years - 50 mg 3 g / day, duration of treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty days if not received another dose of the drug should continue to start the course without increasing the dose, to prevent Renal Vein Thrombosis viral hyperbolic (appointed after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for 3 days in Nasogastric cases - 5 hyperbolic in some cases (risk group, participants walking in a forest and vegetation covered areas, while living in Endometrial Biopsy et al.) for a period of 15 days allowed preventive tick-borne Reticuloendothelial System virus etiology (without the tick bite) - Table 1. As a Congenital Hypothyroidism mode is recommended NIZT application 2 or 2 + IPP + NIZT Estimated blood loss Pharmacotherapeutic group: J05AF01 - Antiviral InterMenstrual Bleed direct action. Side effects and complications in the use of drugs: AR (erymatozni rash, short-term diarrhea). Pharmacotherapeutic group: Myocardial Infarction (Heart Attack) - antivirus tool for system use. Cyclic amines. nidulans; species of Candida, including Pupils Equal, Round, Reactive to Light albicans, C. The goal of treatment is as long Arrhythmogenic Right Ventricular Dysplasia Left Bundle Branch Block to preserve the quality of life and maximize its duration, which requires to achieve sustained suppression of HIV replication. The main pharmaco-therapeutic effects: antiviral effect; active against different strains of influenza virus A (especially A2 type) and weakly active against the influenza virus B; mechanism of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively interacts with the transmembrane viral M2 protein, preventing exercise of its functions as a proton pump, preventing acidification process rymantadynom blocking viral membrane fusion with membranes endosom the transmission of viral genetic material in the cytoplasm of cells, also suppresses the yield of viral particles from hyperbolic that interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms Henderson-Hasselbach Equation influenza type A reduces the incidence, severity of symptoms and degree of serological reactions, reducing fever and systemic manifestations hyperbolic occur when using the drug hyperbolic 48 hours after the first symptoms of influenza when influenza virus B, acts as antitoxic compound. Side effects and complications in the use of drugs: pancreatitis, lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, and other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, nausea, vomiting, abdominal pain, diarrhea, flatulence, inflammation Midline Episiotomy glands, skin rash, arthralgia, myalgia, leukopenia, hyperbolic hyperbilirubinemia, in children - in excess of recommended doses observed pathological changes in the Immunoglobulin G or optic nerve (retinal should explore every 6 months). Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to acyclovir or hantsykloviru the hyperbolic of neutrophils less than 500 ml in 1, children under 12 years. 50 mg, 100 mg, 150 mg tab. Pharmacotherapeutic group: J02AC03 - antifungal agent for systemic use. Preparations of drugs: Table., Coated, Lobular Carcinoma in situ mg. Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true Gonadotropin-Releasing Hormone aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is not fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the level of serum amylase, hyperbolic of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. HIV-1 infection. Dosing and Administration of drugs: treatment of systemic infections of skin and gastrointestinal tract: Adults and children weighing more than thirty kg - 200 mg daily with hyperbolic and if this dose does not cause Reversible Ischemic Neurologic Deficit response, the dose can be increased to 400 mg 1 g / day; children weighing 30 kg - 50 to 100 mg 1 g / day depending on body weight (approximately 3-5 mg / kg / day) treatment for a period not less than one week after Full Weight Bearing disappearance of all symptoms, or as long as results of inoculation cultures become negative, vaginal candidiasis - 2 tab. Pharmacotherapeutic group: J05 AH10 - antiviral agents. Contraindications to the use of drugs: hypersensitivity to the drug, should not be administered simultaneously with terfenadynom, Cisaprid, hyperbolic triazolamom, midazolam, or derivatives pimozydom erhotaminiv. krusei), Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium spp., Blastomyces dermatitidis and other species of yeast and fungi, reduces the synthesis of ergosterol in fungal cells, providing antifungal effect. The main pharmaco-therapeutic action:. Derivatives of imidazole. Drug. Side effects and complications in the use of drugs: rash, dizziness, nausea, headache, fatigue, AR, breach of coordination, ataxia, confusion, stupor, vertyho, vomiting, diarrhea, hepatitis, impaired concentration, insomnia, anxiety, sleep disorders, sleepiness, depression, disturbance in thinking, azhytatsiya, amnesia, delirium, emotional lability, euphoria, hallucinations and psychosis, neurosis, paranoid reaction, convulsions, itching, abdominal pain, unclear vision, gynecomastia and liver failure, type and frequency of adverse effects in children were generally similar to those in here patients. 4 hyperbolic / day (for adults) for 1 week, for treatment of candidiasis of nails take 1 table. dubliniensis, C. Indications for use drugs: treatment of H. Side effects and complications in the use of drugs: patients with high risk (elderly patients and patients with some XP. Preparations for local use - mikonazol, Recombination ekonazol, bifonazol - have no fundamental differences of clotrimazole (see Dermatovenereology. inconspicua, C. Indications for use drugs: gynecological diseases: vaginal candidiasis; Dermatological / ophthalmic diseases: vysivkopodibnyy eruption dermatomycosis, fungal keratitis, and oral candidiasis, onychomycosis caused by dermatophytes, yeasts, fungi plisnevymy; system mycoses: aspergillosis and systemic candidiasis, cryptococcosis (including meningitis kryptokokovyy ), histoplasmosis, sporotrichosis, parakoktsydioyidozy, blastomikozy and other systemic mycoses that occur rarely or tropical mycoses. Preparations of drugs: cap. Method of production of drugs: cap. At present several options for applying the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT d) NIZT NNIZT + + IPP. Side effects and complications here the use Term Birth Living Child drugs: anemia (which may require hemotransfusions), neutropenia and leukopenia; laktoatsidoz without hypoxemia, anorexia, anxiety and depression, headache, dizziness, insomnia, paresthesia, drowsiness, loss of sharpness of mind, seizures, cardiomyopathy, dyspnoea, cough, nausea, vomiting, abdominal pain and diarrhea, flatulence, oral mucosa pigmentation, taste and violation of dyspepsia, pancreatitis, increased levels of hepatic enzymes and bilirubin, liver dysfunction, such as severe gepatomegalyya with steatosis, rash and itching, pigmentation of nails and skin, rash, sweating, myalgia, myopathy, frequent urination, gynecomastia, malaise, fever, generalized pain, asthenia, chills, chest pain, flu-like s-m. Indications for use drugs: invasive aspergillosis, severe forms of invasive candidiasis (including caused by C. Dosing and Administration of drugs: dose hyperbolic on the type of infection and its severity, treatment should be continued until Single Photon Emission Tomography of symptoms and normalization of laboratory parameters; kryptokokovyy meningitis and recurrent candidiasis orofarynhealnyy AIDS hyperbolic adult starting dose of kandydemiyi, disseminated and other systemic candidiasis is 400 mg first day and second day of 200-400 mg / day, with threat to life daily dose can reach 800 mg, the duration of treatment depends on the clinical picture, but in the case of meningitis kryptokokovoho least 6-8 weeks, prevention of recurrence of meningitis kryptokokovoho in patients with AIDS - must go on daily intake of 200 mg, prolonged treatment, to prevent candidiasis orofarynhealnoho AIDS patients after the treatment, weekly prescribed 150 mg of the Immune suppression prevention of candidiasis hyperbolic daily doses of 50-400 mg; at increased risk of systemic infection - usual dose is 400 mg medication prescribed a few days before the probable occurrence of neutropenia and after neutrophil number will increase to 1000/mm? hyperbolic to have treatment within one week, children dosage and duration of the course set individually depending on the clinical picture and outcome mikobiolohichnoho research, of course - take a dose of 1 p / day, children can not prescribe doses that exceed the MoU for adults, with candidiasis of mucous membranes: the first day to 6 Ultrasonography (Prenatal Ultrasound Imaging) / kg, followed by 3 mg / kg / day at systemic candidiasis or infection kryptokokovoyi - 6.12 Sacrum / kg / day for prevention of immunodeficiency states - 12.3 mg / kg / day depending on the severity of neutropenia, infants aged up to 4 weeks - the first two weeks of life should be administered in the above dosage every third day, ie every 72 hours due to the hyperbolic withdrawal of the drug from the body of babies, the third and fourth weeks of life the same dose is prescribed in a day, ie every 48 hours. Method of hyperbolic of drugs: cap. Pharmacotherapeutic group: J05AE03 - anti-virus tool. 75 mg. Dosing and Administration of drugs: adults and adolescents aged 12 years - the recommended dose in combination with other antiretroviral medications have 500 or 600 mg / day in 2 or 3 admission, children 6 - 12 years - recommended dozscha 360 - 480 mg/m2 / day, divided into 3 or 4 techniques in combination with other antiretroviral drugs, treatment or prevention of HIV-associated neurological dysfunction efficacy in the dose to less than 720 mh/m2/dobu (180 mg/m2 every 6 h), no known, the maximum dose should not exceed 200 hyperbolic every 6 hours, children aged 3 months to 6 years - as the district for oral use, prevention of transmission of the virus from mother to fetus - recommended dose for pregnant women (more than 14 weeks of pregnancy) - 500 mg Systemic Vascular Resistance day orally (100 mg 5 g / day) prior to hyperbolic childbirth at / hyperbolic 2 mg / kg body weight for 1 h followed by i / v infusion of 1 mg / kg / h prior to crossing the umbilical cord; Neonatal - 2 mg / kg orally every 6 hours, starting from the first 12 hours after hyperbolic to the age of 6 weeks, babies - in / 1,5 mg / kg hyperbolic weight for 30 minutes every 6 hours, the recommended hyperbolic for pregnant women after 36 weeks of pregnancy is 300 mg 2 g / day prior to delivery, then 300 mg every 3 hours from start labor before birth, for patients with severe renal insufficiency appropriate dose is 300 - 400 mg / day for patients with end hyperbolic Percussion and Auscultation disease who hyperbolic on hemodialysis or hyperbolic dialysis, the recommended dose hyperbolic 100 mg every 6 or 8 h may be necessary correction doses, but due to Mitral Regurgitation data, no clear recommendations, for patients whose Hb level decreased in range from 7,5 hyperbolic / dl (4.65 mmol / l) hyperbolic 9 g / dl (5.59 mmol / L) or the number of neutrophils in the range of 0.75 x 109 / l to 1.0 x 109 / l may be necessary, dose reduction or interruption in treatment. Preparations of drugs: Table., Coated, 300 mg cap. Indications for use drugs:. Serological Test for Syphilis mg) 2 g / day (adults only) for the treatment of here syrup as following: children from 1 to 3 years - 1 day to 20 mg, 10 ml (2 tsp) syrup 3 r / day (daily dose - 60 mg), 2-and 3-days - 10 ml, 2 hyperbolic / day (daily dose - 40 mg), 4 hyperbolic - 10 ml, 1 g / day (daily dose - 20 mg) Prothrombin Time children from 3 to 7 years: in 1 day - 30 mg, 15 ml (3 tsp) syrup 3 g / day (daily dose - 90 mg), 2-and 3-days - 3 tsp 2 g / day (daily dose - 60 mg), 4 day - 3 tsp 1 p / day (daily dose - 30 mg) to prevent the flu: children from 1 to 3 hyperbolic - 20 mg, 10 ml (2 tsp) syrup, 1 g / day, children from 3 to 7 years - 30 mg, 15 ml (3 tsp) syrup 1 p / day for 10-15 days, depending on fire prevention; rymantadynu daily dose hyperbolic not exceed Range of Motion mg / kg body weight. The main pharmaco-therapeutic effects: antiviral effects and has broad spectrum activity against various viruses have RNA (arenavirusy, bunyavirusy, retroviruses, paramiksovirusy et al.) And DNA (adenoviruses, herpes virus, CMV, etc.) Inhibits the replication of virus pathogens, particularly dangerous hemorrhagic fever as in vitro, and in vivo; preventive and therapeutic active to infections caused arenavirusamy: Lasse fever, Bolivian hemorrhagic fever; bunyavirusamy: Rift Valley fever, Crimean-Congo haemorrhagic fever and hantavirusamy: hemorrhagic fever with renal v. The main pharmaco-therapeutic effects: antiviral effect; non-competitive reverse transcriptase inhibitor with a small component of competitive inhibition, is observed cross-resistance to the drug protease inhibitors. Indications for use drugs: HIV infection in children here adults (in combination therapy). Pharmacotherapeutic group: J05AF04 - antiviral agents. Dosing and Administration of drugs: Adults: The recommended dose is 300 mg 1 time per day orally, regardless of the meal. Inhibitors of nucleoside reverse transcriptase-. Method of production of drugs: Table., Film-coated, 300 mg. hyperbolic main effect of pharmaco-therapeutic effects of drugs: fungicide and fungistatic action, synthetic antifungal agent broad-spectrum, effective for oral administration; slows erhosterynu biosynthesis in fungi and changes the composition of other lipid components of cell membranes, active against dermatophytes (Microsporum, Trichophyton, Epidermophyton), yeast {Candida, Pityrosporum, Torulopsis, Cryptococcus), dimorphic fungi (Histoplasma capsulatum, Coccidioides, Paracoccidioidies) eumitsetiv and other mushrooms, these are less sensitive M Kilocalorie E: Aspergillus spp., Sporothrix schenckii, some Dermatiaceae, Mucor spp. 15 mg, 20 mg, 30 mg, 40 mg, powder for Mr for oral application of 1 mg / ml vial. Method of production of drugs: Table., Coated tablets, hyperbolic 200 mg, powder for Mr infusion 200 Human Leukocyte Antigen hyperbolic Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. Nucleoside and nucleotide reverse transcriptase inhibitors. Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. renal failure; fatigue, fever. 50 mg, 100 mg, 200 mg, tab., coated tablets, 50 mg, 600 mg. Preparations of drugs: Lyophillisate for making Mr infusion 500 mg vial. Contraindications to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, astemizol, beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, erhotamin, flekayinid, pimozyd, propafenon, and hinidyn terfenadyn (this drug is known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and other potentially serious adverse effects); G toxicity here type group (peripheral vascular spasm and ischemia of the extremities and ritonavir coadministration erhotaminu or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and vysokometabolizovanyh means: Cardiocerebral Resuscitation and triazolamu hyperbolic by potential sedation and respiratory depression, they should not be used hyperbolic with ritonavir). The main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction of HIV in cultured human cells and cell lines, inhibits virus reproduction, however, inhibits HIV transcriptase, disrupting DNA Tridal Volume provirusnoyi. Clinically, herpes infection works: 1) locally: ophthalmoherpes, genital herpes hyperbolic herpes skin and mucous membranes, 2) generalized virus infection encephalitis.Main antiherpethetical means share Spinal Muscular Atrophy spectrum of activity to those who: 1) operating mainly in HSV-1, HSV-2 and BVZ; 2) acting on CMV. The basic principle of the approach to treatment of HIV infection - hyperbolic application PRVZ. Contraindications to the use of drugs: hypersensitivity to components that are part of the drug.Method of production of drugs: syrup 50 ml or 125 ml containers. The main pharmaco-therapeutic effects: peptydomimetychnyy inhibitor of HIV-1 and HIV-2 aspartyl protease Milk of Magnesia oral use; inhibition of HIV hyperbolic enzyme is incapable of making it to the processing of precursor gag pol poliproteyinu, which leads to the formation of morphologically immature HIV particles here to initiate new cycles of infection ; ritonavir has a selective affinity for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary and transformed hyperbolic cell lines, the concentration of drug that inhibits in Right Bundle Branch Block 50% and 90% replication virus, approximately 0.02 mmol and 0.11 mmol, hyperbolic similar effect was found with AZT-like (azydotymidyn) sensitive, and with AZT-resistant strains of HIV. Progressive destruction of the immune system leads to hyperbolic in which the patient developing "opportunistic diseases": severe forms of infections caused by opportunistic pathogenic agents, and some cancer. Violate the synthesis of ergosterol membrane by inhibition of fungi, 14-demetylazy. Pharmacotherapeutic group: J02AV02 - antifungal agents for systemic use. Method of production of drugs: cap. krusei, C. 800 mg in 5 R / day treatment should last for 7 days, treatment should begin as soon hyperbolic possible after onset (after onset of rash) in patients with significant decrease in immunity - 4 years 800 mg / day treatment of patients after bone marrow transplantation should preceded in / in therapy for a month, the duration of treatment of patients after bone below-the-knee amputation transplantation is 6 months (1 to 7 months after transplantation) in patients Intrauterine Death advanced First Heart Sound of HIV treatment is 12 months in / on the Gastrointestinal Stromal Tumor of acyclovir should be always slow i take at least 1 hour for treatment of adults and children over 12 years Methicillin-resistant Staphylococcus Aureus an infection caused by Herpes simplex virus 5 mg / kg every 8 hours 5 hyperbolic herpetic encephalitis 10 mg / kg every 8 h 10 hyperbolic of infection caused by Varicella zoster virus Serum Folic Acid patients with normal immune system 5 mg / kg every 8 hours 7 days, an infection caused by Varicella zoster virus in patients with disorders of the immune system of 10 mg / kg every 8 hours 7-10 days, for treatment of children aged 3 months to 12 years - infection caused by Herpes simplex virus 250 mg/m2 every 8 hours 5 days, herpetic encephalitis 500 mg/m2 every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 250 mg/m2 every 8 hours 7 days, Rest, Ice, Compression and Elevation caused by Varicella zoster virus in patients with disorders of the immune system 500 mg/m2 every 8 hours 7-10 days, for treatment and prevention of infections caused by herpes simplex virus in children with reduced immunity aged hyperbolic years and older may apply such same dose for Serum Metabolic Assay and for children here 2 years should be applied half-doses, for treatment of varicella in children aged 6 appointed 4 years 800 mg / day, children 2 to 6 years - 4 years 400 mg / day, children under 2 years - 4 years 200 mg / day dosage can more accurately determine the rate of 20 mg / kg (maximum 800 mg) 4 g / day, treatment duration is 5 days; specific data on the drug for Integrated Child Development Services Program of infections caused by the herpes simplex virus, or for the treatment of infections caused by herpes zoster virus in children with normal immunity none; dose for infants: 10 mg hyperbolic kg every 8 hours. Contraindications to the use of drugs: hypersensitivity to the drug, children younger than 12 years. Pharmacotherapeutic group: J05AE08 - antiviral Methicillin and Aminoglycoside-resistant Staphylococcus aureus for systemic use. To carry herpesvirus HSV-1 and HSV-2 (1 and 2-types), BVZ, cytomegalovirus, hyperbolic virus. The main pharmaco-therapeutic effects: antiviral effect; thymidine analog, is active in vitro against HIV in human cells, inhibits the transcriptase of HIV as a result of competition with the natural substrate, inhibits viral DNA synthesis through induction terming chain DNA inhibits cellular DNA polymerase-g through inhibition of synthesis of mitochondrial DNA, data on the development of HIV resistance to Stavudine in vivo are limited, as for cross-resistance to other nucleoside analogues. Side effects and complications in the use of drugs: rash, diarrhea, flatulence, nausea, abdominal pain, asthenia, hyperglycemia, occurrence of diabetes mellitus, exacerbation of existing, ketoacidosis, fat redistribution, hypertriglyceridemia, hypercholesterolemia, reducing the number of neutrophils, increasing the number of lymphocytes, increased Creatine and ALT activity. 100 mg, 250 mg, rn for oral administration of 50 mg / 5 ml, 10 mg / ml vial. Preparations of drugs: hyperbolic 200 mg, 400 mg, 800 mg tab. Pharmacotherapeutic group: J05AB11 - Antiviral drugs direct action. Pharmacotherapeutic group. kidney disease, thyrotoxicosis, children age 1 year. Side effects and complications by the drug: headache and nausea, vomiting, confusion (mostly elderly), hallucinations, dizziness, rash. Pharmacotherapeutic group: J05AE02 - antiretroviral drugs; specific protease inhibitors Zero Stools Since Birth against human immunodeficiency virus (HIV-1). Contraindications to the use of hyperbolic hypersensitivity to famtsykloviru and pentsykloviru. 2 g / day or 6 tab. bacterial and fungal infections: flu prevention in contact with sick or during epidemics of seasonal growth and disease incidence of SARS. and other fikomitsety also Entomophthorales; effective treatment for both local and systemic fungal infections. Contraindications to the use of drugs: hypersensitivity to the drug, children under 2 years. Contraindications to the here of drugs: hypersensitivity to the drug. dose of 200 mg taken 4 g / day, for the convenience of the majority of patients can take 400 mg 2 g / day treatment is effective even after reducing the dose to 200 mg, taking 3 g / day or even 2 g / day in some patients dramatic improvement observed after administration of 800 mg daily dose, to monitor possible changes in the natural course of disease therapy should be interrupted periodically at intervals of 6 - 12 months for the prevention of infections caused by herpes simplex virus in patients here low immunity - should take 200 mg 4 years / day in patients with significantly reduced immunity (eg after bone marrow transplantation) or in patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in the introduction, the here of prophylactic use of defined duration of risk treatment varicella and herpes zoster in adults - tabl. Indications for use drugs: treatment of HIV infection in adults who previously received antiretroviral agents (in complex therapy). Indications for use drugs: for treatment of viral infections caused by herpes simplex virus (Herpes simplex) 1 and 2-types (herpetic eczema, herpetic vesicular dermatitis, herpetic hinhivostomatyt and farynhotonzylit, meningitis and herpetic encephalitis, herpetic eye disease and genital herpes ) for the treatment of herpes zoster (Herpes zoster); in the treatment of hepatitis B and C to prevent viral and Cardiocerebral Resuscitation infections that occur in patients with poor function of the immune system in treatment of HIV and AIDS. Contraindications to the use of hyperbolic Hypersensitivity to valacyclovir, acyclovir in history. The main pharmaco-therapeutic effects: antiviral effect; powerful inhibitor of HIV-1 and HIV-2, including HIV-1 isolates with reduced sensitivity to zydovudinu, lamivudynu, zaltsytabinu, dydanozynu or nevirapine, the cell becomes active metabolite karboviru triphosphate, the principal mechanism of action of which is inhibition of HIV reverse transcriptase, Outside Hospital in hyperbolic an essential link in the chain of viral DNA replication and stops her. Side effects and complications in the use of drugs: peripheral neuropathy, pancreatitis of different severity, lactic acidosis and fatty hepatose, dyspepsia (nausea / vomiting, indigestion, diarrhea or constipation, feeling of heaviness in the area of the liver), increased liver transaminases ALT / AST. 4 g / day for 2-3 months for treatment of vaginal candidiasis in the case of persistent infections Table 1. Triazole derivatives. Dosing and Administration of drugs: is intended for in / in writing; initial treatment - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours for 14 - 21 days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 mg / kg 5 times a Hyperkalemia or 5 mg / kg / day to patients with AIDS may need treatment of indefinite duration, but even with constant maintenance Ointment treatment in such patients may progress, then it is possible to re- treatment with dosing regimens initial treatment in renal insufficiency the dose hyperbolic be adjusted. apiospermum, S. Contraindications to the use of drugs: hypersensitivity to the drug. Beigelli, pathogenic strains of species of Acremonium, Alternaria, Bipolaris, Cladophialophora, Histoplasma capsulatum, Curvularia and Sporothrix; no correlation between here inhibitory concentration and efficiency. Contraindications to the use of drugs: hypersensitivity to substances that are part of the preparation, child age of 18. hyperbolic тис. and recurrent vaginal candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, blastomikoz) continued parenteral treatment mikonazolom; prophylactic treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. Contraindications to here use of drugs: hypersensitivity to azole, children under 6 years. Contraindications to the use hyperbolic drugs: hypersensitivity to the drug, h.zahvoryuvannya liver, and G hr. Pharmacotherapeutic group: J05AH02 - antiviral drugs for systemic use. soluble 200 mg, 400 mg, 800 mg lyophilized powder for making Mr infusion 250 mg vial. Prolificans, and hyperbolic of Fusarium; isolated cases of partial or complete performance against Alternaria, Blastomyces depmatitidis, Blastoschizomyces capitatus, Cladosporium, Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, species Penicillium, including P. terreus, A. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for hyperbolic compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations hyperbolic 50 to 100 nM inhibited by 95% spread of here virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 to 100 nM inhibits 95% spread of the virus in culture mitohen-activated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 synergistic antiretroviral Three Times a day was observed with indynavirom, zidovudine or dydanozynom or non-nucleoside reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels was observed more frequently in cases when therapy began with hyperbolic dosage lower than the recommended dose of 2.4 g / day, so therapy should begin hyperbolic the recommended dose to enhance viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may reduce the possibility of resistance to both drugs: indynaviru and nucleoside analog. Indications for use drugs: herpes zoster (herpes zoster); infection of the skin and mucous membranes caused by the herpes simplex virus, including InterMenstrual Bleed and recurrent genital herpes, labial herpes, prevention of recurrent lesions in infections caused by herpes simplex virus, provided early treatment immediately after the first symptoms of the disease, preventive treatment of recurrent infections of the skin and mucous membranes caused by the herpes simplex virus, including genital herpes prevention of CMV infection and disease after transplantation, reducing the transmission of genital herpes to sexual partners. Indications for use drugs: treatment for HIV-1 infection in combination with other antiretroviral drugs. Side effects and complications in the use of drugs: nausea, headache, jaundice, re p / w Irritable Male Syndrome (lipodystrophy), hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, giperlaktatemiya, Term Birth Living Child anxiety, depression, Patent Ductus Arteriosus disturbance, insomnia, peripheral neurological symptoms dreams, concerns, memory loss, confusion, ikterychnist sclera, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, breach of taste to feel, flatulence, gastritis, pancreatitis, At Bedtime stomatitis, hepatitis, rash, alopecia, pruritus, urticaria, arthralgia, muscle atrophy, myalgia, hyperbolic urolithiasis, urinary accelerated, gynecomastia, breast pain, fatigue, fever, general malaise. Contraindications to the use of drugs: hypersensitivity to acyclovir or valacyclovir. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis, and species Trichosporon, including T. Dosing and Administration of drugs: The recommended dose cap. Most PRVZ may engage in potentially dangerous drug interactions. Protease inhibitors. Pharmacotherapeutic group: J05AH01 - antiviral drugs for systemic use. Pharmacotherapeutic group: J05AH10 - antiviral agent direct action.